We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

16 hedge funds and large institutions have $2.3M invested in Acorda Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

18% more capital invested

Capital invested by funds: $1.94M → $2.3M (+$357K)

7% more funds holding

Funds holding: 15 → 16 (+1)

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
3
Closed
2
Calls
$48K
Puts
–
Net Calls
+$48K
Net Calls Change
-$208K

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$162K
2
Renaissance Technologies
Renaissance Technologies
New York
+$7.53K
3
UBS Group
UBS Group
Switzerland
+$2.02K
4
TRCT
Tower Research Capital (TRC)
New York
+$497
5
BlackRock
BlackRock
New York
+$30

Top Sellers

1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$7.56K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$6.62K
3
Group One Trading
Group One Trading
Illinois
-$3.07K
4
Morgan Stanley
Morgan Stanley
New York
-$1.51K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$13
Name Holding Trade Value Shares
Change 		Change in
Stake
DKCM
1
Davidson Kempner Capital Management
New York
$750K – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$690K +$7.53K +500 +1%
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$489K -$6.62K -440 -1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$161K +$162K +10,734 New
BlackRock
5
BlackRock
New York
$102K +$30 +2 +0%
Wells Fargo
6
Wells Fargo
California
$56.1K – – –
Deutsche Bank
7
Deutsche Bank
Germany
$25.5K – – –
Morgan Stanley
8
Morgan Stanley
New York
$17.6K -$1.51K -100 -8%
Russell Investments Group
9
Russell Investments Group
United Kingdom
$4.37K – – –
UBS Group
10
UBS Group
Switzerland
$2.01K +$2.02K +134 New
TRCT
11
Tower Research Capital (TRC)
New York
$615 +$497 +33 +413%
First Manhattan
12
First Manhattan
New York
$44 – – –
JP Morgan Chase
13
JP Morgan Chase
New York
$29 +$15 +1 +100%
Osaic Holdings
14
Osaic Holdings
Arizona
$29 +$15 +1 +100%
Qube Research & Technologies (QRT)
15
Qube Research & Technologies (QRT)
United Kingdom
$15 +$15 +1 New
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
– -$7.56K -502 -97%
Group One Trading
17
Group One Trading
Illinois
– -$3.07K -204 Closed
Fidelity Investments
18
Fidelity Investments
Massachusetts
– -$13 -1 Closed

ACOR Hedge Fund Activity: Q3 2023 in Review

16 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2023, worth a combined $2.3M — up 18% from $1.94M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ACOR positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $162K. The largest seller was Royal Bank of Canada, cutting an estimated $7.56K.

  • 16 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2023, up from 15 in Q2 2023.
  • Funds reported $2.3M of Acorda Therapeutics stock for Q3 2023, up 18% quarter-over-quarter.
  • 3 funds opened new Acorda Therapeutics positions in Q3 2023 and 2 closed out, a net change of +1 holder.
  • The largest Acorda Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $162K added.
  • The largest Acorda Therapeutics seller in Q3 2023 was Royal Bank of Canada, an estimated $7.56K sold.

Based on aggregated 13F filings for Q3 2023.